CGONCG Oncology, Inc.
- GlobeNewswire
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk and high-grade Ta NMIBC anticipated November 2026BOND-003 Cohort P and CORE-008 Cohort CX 12-month data ...
- GlobeNewswire
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
DALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. A highly accomplished biopharmaceutical executive with more ...
- PR Newswire
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. (NASDAQ: CGON) breached their fiduciary duties to ...
- Earnings Call Transcripts
Morgan Stanley 24th Annual Global Healthcare Conference - CG ONCOLOGY INC
Hi everyone, my name is Sean Lam and I'm the Head of US Mid-Cap Biotech Equity Research here at Morgan Stanley and welcome to our Global Healthcare Conference. Before we begin, to make you aware of some important disclos ...
- Earnings Call Transcripts
CGON - 1775835 - CG ONCOLOGY INC
Hi everyone, my name is Sean Lam and I'm the Head of US Mid-Cap Biotech Equity Research here at Morgan Stanley and welcome to our Global Healthcare Conference. Before we begin, to make you aware of some important disclos ...
- GlobeNewswire
CG Oncology to Present at Upcoming Investor Conferences in September
DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the ...
- PR Newswire
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. (NASDAQ: CGON)... ...
- Analyst Upgrades
RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79
RBC Capital analyst Leonid Timashev maintains CG Oncology with a Outperform and lowers the price target from $81 to $79. ...
- Analyst Upgrades
Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $85
Piper Sandler analyst Kelsey Goodwin maintains CG Oncology with a Overweight and raises the price target from $82 to $85. ...
- Analyst Upgrades
Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85
Truist Securities analyst Gregory Renza maintains CG Oncology with a Buy and raises the price target from $82 to $85. ...
- GlobeNewswire
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected fourth quarter ...
- GlobeNewswire
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
DALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced the publication of results from the pivotal Phase 3 BOND-003 Cohort C trial evaluating cretostimogene grenadenorepvec ...
- GlobeNewswire
The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution
DENVER, June 25, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Cancer treatment is undergoing one of the most significant transformations in modern medical history. For decades, physicians relied primarily on ...
- Earnings Call Transcripts
JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - CG ONCOLOGY INC
Good morning, everyone. Thank you to those in the room and to those dialed in on the webcast as well. My name is Faisal Khurshid. I'm one of the senior biotech analysts here at Jefferies, and we are here live at the Jeff ...
- GlobeNewswire
CG Oncology to Present at Upcoming Investor Conferences in June
DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the ...
- Analyst Upgrades
Wolfe Research Initiates Coverage On CG Oncology with Peer Perform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on CG Oncology with a Peer Perform rating. ...
- GlobeNewswire
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCLast year's awardees recently ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $100 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates CG Oncology with a Buy and maintains $100 price target. ...
- GlobeNewswire
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat ...
- Analyst Upgrades
Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $82
Truist Securities analyst Gregory Renza reiterates CG Oncology with a Buy and raises the price target from $77 to $82. ...
- GlobeNewswire
CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented- -Visit CG Oncology at booth #3051- DALLAS, May ...
- Analyst Upgrades
JP Morgan Maintains Overweight on CG Oncology, Raises Price Target to $96
JP Morgan analyst Brian Cheng maintains CG Oncology with a Overweight and raises the price target from $91 to $96. ...
- Analyst Upgrades
CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings
CG Oncology reported mixed results for Q1, with losses of 71 cents per share and sales of $1.083 million. Analysts have adjusted price targets. ...
- Analyst Upgrades
RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $81
RBC Capital analyst Leonid Timashev maintains CG Oncology with a Outperform and raises the price target from $79 to $81. ...
- Analyst Upgrades
Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $77
Truist Securities analyst Gregory Renza reiterates CG Oncology with a Buy and raises the price target from $75 to $77. ...